51
Participants
Start Date
August 31, 2022
Primary Completion Date
July 31, 2025
Study Completion Date
December 31, 2025
emicizumab
This study design uses emicizumab as a prophylaxis treatment to prevent bleeding for all participants, bypassing agents (with the exception of aPCC) and treatment of concomitant diseases will be given as clinically indicated. All eligible subjects with AHA will receive the same study medication consisting of: two loading doses of the emicizumab on day 1 and 2 followed by once weekly subcutaneous emicizumab injections. Immunosuppressive therapy (IST) will be given concurrently as per investigator discretion.
RECRUITING
Hemophilia Center of Western Pennsylvania, Pittsburgh
RECRUITING
Penn Blood Disorders Program, Hospital of the University of Pennsylvania, Philadelphia
RECRUITING
Georgetown University, Washington D.C.
RECRUITING
UVA Comprehensive Cancer Center, Charlottesville
RECRUITING
University of North Carolina, Chapel Hill
RECRUITING
Emory University, Atlanta
RECRUITING
Indiana Hemophilia and Thrombosis Center, Inc., Indianapolis
RECRUITING
Versiti Inc., Milwaukee
RECRUITING
Mayo Clinic, Rochester
RECRUITING
Bleeding and Clotting Disorders Institute, Peoria
RECRUITING
Washington University, St Louis
RECRUITING
University of Oklahoma Health Sciences Center, Oklahoma City
RECRUITING
UCSD Hemophilia and Thrombosis Treatment Center, San Diego
RECRUITING
Washington Center for Bleeding Disorders, Seattle
RECRUITING
Tulane University, New Orleans
RECRUITING
University of Vermont Medical Center, Burlington
Collaborators (1)
Genentech, Inc.
INDUSTRY
University of Washington
OTHER